MaxCyte is a leader in cell transfection and modification platforms, bringing to market its patented flow electroporation technology for use in the discovery and development of small molecule drugs, biotherapeutics and innovative cellular therapeutics. MaxCyte’s proprietary flow technology uniquely fulfills the needs for high quality, fully scalable cell modification.
The MaxCyte® STX™ Scalable Transfection System was designed for the rapid development and consistent production of (co)transfected primary cells, stem cells, and cell lines for cell-based screening assays for ion channels, GPCRs, and other targets, with superior performance and flexibility with Seamless Scalability™ from the bench to HTS scale.
The MaxCyte technology has been proven through over a decade of use in the clinical applications, inlcuidng a Master File designation with the CBER Division of the U.S. FDA and clearance by NIH's RAC and Health Canada. The MaxCyte system can be used to develop cell therapeutics for a variety of diseases and can be used to load cells for both autologous and allogeneic therapies.
Paul Sharpe‘Membership Status’ indicates whether this member is an active reviewer on the site, and how many reviews have been published.
|Status:||No. Reviews Published:|
To be seen as an authority on SelectScience, find your products to review today., AstraZeneca
09 Sep 2011
MaxCyte Showcases Innovations in High-Throughput Transfection for Cell-based Assays & Difficult-to-Transfect Cells
30 Aug 2011
27 May 2011
MaxCyte Highlights Innovations in High-throughput Transfection for Cell-based Assays & Protein Production
21 Mar 2011
Expression of Functional Ion Channels Using the MaxCyte STX Demonstrated in Automated Electrophysiology Assays
09 Mar 2011
Increased Laboratory Productivity for CHO Cell Antibody Production Using Scalable Transient Gene ExpressionMaxCyte
16 Nov 2012
Development of Fully Scalable Reporter Gene Assays for Studying Transcriptional Regulation and Receptor Activation using Flow ElectroporationMaxCyte
16 Nov 2012
31 Oct 2011
Rapid Development of a High Titer Protein Production Method with CHO Cells Transiently Transfected using MaxCyte Electroporation TechnologyMaxCyte
26 May 2011
High Throughput Transfection of Stem Cells, Primary Cells and Difficult-to-Transfect Cell Lines: Jurkat, CHO, Human Skeletal Muscle Cells & Primary Neuronal Cell Transfection using a Scalable, Electroporation-Based Technology.MaxCyte
28 Mar 2011